Transforming growth factor-β1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation.

[1]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[2]  T. Chao,et al.  A Novel Finding of the Atrial Substrate Properties and Long‐Term Results of Catheter Ablation in Chronic Atrial Fibrillation Patients with Left Atrial Spontaneous Echo Contrast , 2012, Journal of cardiovascular electrophysiology.

[3]  José Jalife,et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation , 2012, Heart rhythm.

[4]  Daniel Steven,et al.  Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. , 2011, Heart rhythm.

[5]  Chengwen Sun,et al.  20-Hydroxyeicosatetraenoic acid induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways. , 2011, Journal of cardiovascular pharmacology.

[6]  P. Zimetbaum,et al.  Atrial Fibrillation and Atrial Fibrosis , 2010, Journal of cardiovascular pharmacology.

[7]  H. Pak,et al.  High plasma concentrations of transforming growth factor-β and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[8]  Ethan M Balk,et al.  Predictors of Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation: A Systematic Review , 2010, Cardiovascular Electrophysiology.

[9]  Tadashi Fujino,et al.  Clinical Characteristics of Patients With Persistent Atrial Fibrillation Successfully Treated by Left Atrial Ablation , 2010, Circulation. Arrhythmia and electrophysiology.

[10]  T. Munzel,et al.  Atrial fibrosis and atrial fibrillation: the role of the TGF-β1 signaling pathway. , 2010, International journal of cardiology.

[11]  Jagmeet P. Singh,et al.  Catheter ablation of atrial fibrillation the search for substrate-driven end points. , 2010, Journal of the American College of Cardiology.

[12]  H. Lei,et al.  TGF‐β1 Expression and Atrial Myocardium Fibrosis Increase in Atrial Fibrillation Secondary to Rheumatic Heart Disease , 2010, Clinical cardiology.

[13]  L. Lo,et al.  The Impact of Left Atrial Size on Long‐Term Outcome of Catheter Ablation of Chronic Atrial Fibrillation , 2009, Journal of cardiovascular electrophysiology.

[14]  David O. Martin,et al.  Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. , 2009, Heart rhythm.

[15]  Pyotr G. Platonov,et al.  Clinical predictors of termination and clinical outcome of catheter ablation for persistent atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[16]  Y. On,et al.  Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. , 2009, The Journal of thoracic and cardiovascular surgery.

[17]  Peng-Sheng Chen,et al.  Histopathological substrate for chronic atrial fibrillation in humans. , 2009, Heart rhythm.

[18]  L. Lo,et al.  Predicting factors for atrial fibrillation acute termination during catheter ablation procedures: implications for catheter ablation strategy and long-term outcome. , 2009, Heart rhythm.

[19]  M. Jahangiri,et al.  Current concepts in the pathogenesis of atrial fibrillation. , 2009, American heart journal.

[20]  F. Sacher,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study , 2008, Circulation.

[21]  Shih-Ann Chen,et al.  Consistency of complex fractionated atrial electrograms during atrial fibrillation. , 2008, Heart rhythm.

[22]  S. Nattel,et al.  Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[23]  Xu-ping Li,et al.  The fibrosis and atrial fibrillation: is the transforming growth factor-beta 1 a candidate etiology of atrial fibrillation. , 2008, Medical hypotheses.

[24]  L. Lo,et al.  Biatrial Substrate Properties in Patients with Atrial Fibrillation , 2007, Journal of cardiovascular electrophysiology.

[25]  F. Sacher,et al.  Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial fibrillation. Long-term clinical outcome. , 2007, European heart journal.

[26]  David Tamborero,et al.  Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. , 2007, European heart journal.

[27]  R. Sheppard,et al.  Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmia , 2006, Immunology.

[28]  Sander Verheule,et al.  Increased Vulnerability to Atrial Fibrillation in Transgenic Mice With Selective Atrial Fibrosis Caused by Overexpression of TGF-β1 , 2004, Circulation research.

[29]  G Hindricks,et al.  Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease , 2004, Heart.

[30]  Zoltan Szalay,et al.  Structural correlate of atrial fibrillation in human patients. , 2002, Cardiovascular research.

[31]  M. Allessie,et al.  Electrical, contractile and structural remodeling during atrial fibrillation. , 2002, Cardiovascular research.

[32]  Hakan Oral,et al.  Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation , 2002, Circulation.

[33]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .